Nilvadipine

Summary

Nilvadipine (CHEMBL517427) is a phase-3 clinical-stage small molecule (ATC C08CA10); indicated across 2 conditions including cardiovascular disorder and alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C08CA10
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 385.4 Da · C19H19N3O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL517427
Name	Nilvadipine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	4494
ATC	C08CA10
Molecular formula	C19H19N3O6
Molecular weight	385.4
InChIKey	FAIIFDPAEUKBEP-UHFFFAOYSA-N

SMILES: CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C

IUPAC name: 3-O-methyl 5-O-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Also known as: CL 287,389, CL-287,389, CL-287389, Dl-nilvadipine, Escor, FK 235, FK-235, FR-34235, Nilvadipine, Nilvadipino, Nivadil, Nivadip

Patent coverage: 3,834 distinct patent families (14,439 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 14,435 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Sodium channel protein type 5 subunit alpha, Equilibrative nucleoside transporter 1, Glucocorticoid receptor, Thromboxane A2 receptor, Voltage-gated L-type calcium channel, Nuclear receptor subfamily 1 group I member 2, Type-1 angiotensin II receptor, Prostaglandin G/H synthase 2, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 19 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P22002	8.98	IC50	1.04	nM	CHEMBL_ACT_423556
P22002	7.97	AC50	10.7	nM	CHEMBL_ACT_25119644
SCN5A	6.36	AC50	440	nM	CHEMBL_ACT_25158933
NR1I2	6.09	AC50	814.3	nM	CHEMBL_ACT_25188221
NR1I2	6.05	EC50	890	nM	CHEMBL_ACT_15465496
NR1I2	6	AC50	1006	nM	CHEMBL_ACT_25224373
NR1I2	5.85	EC50	1400	nM	CHEMBL_ACT_15448137
NR1I2	5.72	EC50	1900	nM	CHEMBL_ACT_15463802
NR1I2	5.7	EC50	2000	nM	CHEMBL_ACT_15463756
SLC29A1	5.45	AC50	3590	nM	CHEMBL_ACT_25141603
NR3C1	5.3	AC50	5000	nM	CHEMBL_ACT_25175907
PDE4D	5.09	AC50	8060	nM	CHEMBL_ACT_25185395

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02017340	PHASE3	COMPLETED	A Phase III Trial of Nilvadipine to Treat Alzheimer’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).